Welcome to our dedicated page for Elutia SEC filings (Ticker: ELUT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Elutia Inc. (ELUT) SEC filings page on Stock Titan centralizes the company’s regulatory disclosures from the U.S. Securities and Exchange Commission, with AI-powered tools to help interpret complex documents. Elutia is a regenerative medicine company that develops drug-eluting biomatrix products, and its filings provide detailed insight into how this business is structured, financed and governed.
Key documents for ELUT include Form 10-K annual reports and Form 10-Q quarterly reports, which discuss Elutia’s drug-eluting biomatrix platform, segment information such as historical Device Protection, Women’s Health and Cardiovascular activities, risk factors, and management’s analysis of operating performance. These reports also describe the company’s focus on NXT-41 and NXT-41x in plastic and reconstructive surgery and summarize prior divestitures, including the Orthobiologics business and the CIED/BioEnvelope business.
Elutia files frequent Form 8-K current reports to document material events. Recent 8-Ks have covered the agreement and closing of the sale of its CIED business to Boston Scientific and Cardiac Pacemakers Inc., amendments to its credit facility with SWK Funding LLC, the use of sale proceeds to repay that facility, board changes, and a Nasdaq notice regarding minimum bid price compliance. These filings also attach press releases with financial results and transaction details, giving additional context on cash flows, debt reduction and strategic focus.
Investors can also use this page to access proxy and governance filings when available, as well as any Form 4 insider transaction reports that disclose trades by directors and officers. Stock Titan’s AI features summarize lengthy filings, highlight sections on regulatory risk, litigation related to products such as FiberCel, royalty and revenue interest obligations, and explain how transactions like the BioEnvelope sale affect Elutia’s balance sheet and future plans.
By reviewing ELUT’s SEC filings alongside AI-generated explanations, users can quickly understand the regulatory history, capital structure changes and strategic decisions that shape Elutia’s drug-eluting biomatrix business.
Elutia Inc. furnished an update on its business by submitting a Form 8‑K that includes a press release announcing its financial results for the second quarter ended June 30, 2025. The press release is provided as Exhibit 99.1 and is incorporated by reference into this report. Elutia’s Class A common stock trades on the Nasdaq Capital Market under the symbol ELUT, and the company is identified as an emerging growth company under applicable SEC rules.
Form 4 overview: On 06/21/2025 Elutia Inc. (ELUT) filed a Form 4 detailing equity activity by President & CEO C. Randal Mills, who is also a director.
Transactions:
- 22,473 Class A shares were acquired through the vesting and settlement of an equal number of restricted stock units (RSUs) (Code “M”).
- 8,019 shares were withheld at $1.81 per share to satisfy tax obligations (Code “F”).
The net increase to the executive’s direct holdings is 14,454 shares.
Post-transaction ownership: Mills now directly owns 321,167 Class A shares. Table II shows 22,473 RSUs still outstanding, indicating additional shares may be delivered in future periods.
Award background: The underlying RSU grant was issued on 06/21/2022 for 89,893 units, vesting in four equal annual tranches beginning 06/21/2023. The current filing represents the second scheduled vesting installment.
No open-market purchases or sales occurred, and the form does not cite a Rule 10b5-1 plan. As such, the disclosure reflects a routine insider vesting event with limited immediate market impact for investors.